Vanuytsel Tim, Tack Jan, Farre Ricard
Department of Chronic Diseases, Translational Research Center for Gastrointestinal Disorders, Metabolism and Ageing, Catholic University Leuven, Leuven, Belgium.
Division of Gastroenterology and Hepatology, Leuven University Hospital, Leuven, Belgium.
Front Nutr. 2021 Aug 26;8:717925. doi: 10.3389/fnut.2021.717925. eCollection 2021.
An increased intestinal permeability has been described in various gastrointestinal and non-gastrointestinal disorders. Nevertheless, the concept and definition of intestinal permeability is relatively broad and includes not only an altered paracellular route, regulated by tight junction proteins, but also the transcellular route involving membrane transporters and channels, and endocytic mechanisms. Paracellular intestinal permeability can be assessed by using different molecules (e.g., sugars, polyethylene glycols, Cr-EDTA) and in Ussing chambers combining electrophysiology and probes of different molecular sizes. The latter is still the gold standard technique for assessing the epithelial barrier function, whereas techniques, including putative blood biomarkers such as intestinal fatty acid-binding protein and zonulin, are broadly used despite limitations. In the second part of the review, the current evidence of the role of impaired barrier function in the pathophysiology of selected gastrointestinal and liver diseases is discussed. Celiac disease is one of the conditions with the best evidence for impaired barrier function playing a crucial role with zonulin as its proposed regulator. Increased permeability is clearly present in inflammatory bowel disease, but the question of whether this is a primary event or a consequence of inflammation remains unsolved. The gut-liver axis with a crucial role in impaired intestinal barrier function is increasingly recognized in chronic alcoholic and metabolic liver disease. Finally, the current evidence does not support an important role for increased permeability in bile acid diarrhea.
在各种胃肠道和非胃肠道疾病中,均有肠道通透性增加的描述。然而,肠道通透性的概念和定义相对宽泛,不仅包括由紧密连接蛋白调节的细胞旁途径改变,还包括涉及膜转运蛋白、通道及内吞机制的跨细胞途径。肠道细胞旁通透性可通过使用不同分子(如糖类、聚乙二醇、铬标记乙二胺四乙酸)以及在尤斯灌流小室中结合电生理学和不同分子大小的探针来评估。后者仍是评估上皮屏障功能的金标准技术,而包括肠脂肪酸结合蛋白和连蛋白等假定血液生物标志物在内的技术,尽管存在局限性,但仍被广泛应用。在综述的第二部分,讨论了屏障功能受损在特定胃肠道和肝脏疾病病理生理学中作用的当前证据。乳糜泻是屏障功能受损起关键作用且连蛋白被认为是其调节因子的证据最为充分的疾病之一。炎症性肠病中显然存在通透性增加,但这是原发性事件还是炎症后果的问题仍未解决。在慢性酒精性肝病和代谢性肝病中,肠道 - 肝脏轴在肠道屏障功能受损中起关键作用这一点日益得到认可。最后,当前证据不支持通透性增加在胆汁酸腹泻中起重要作用。
Methods Cell Biol. 2023
United European Gastroenterol J. 2019-1-19
Scand J Gastroenterol. 2006-4
World J Gastroenterol. 2017-3-28
Histochem Cell Biol. 2025-8-29
EBioMedicine. 2025-6-3
Microorganisms. 2025-4-9
Front Nutr. 2025-4-9
Am J Physiol Gastrointest Liver Physiol. 2021-7-1
Scand J Gastroenterol. 2021-4
Int J Psychiatry Clin Pract. 2021-3